First Amendment to Exclusive Distribution Agreement, dated September 27, 2011, by and between RTI Biologics, Inc., and Zimmer Dental Inc

EX-10.7 2 d674465dex107.htm EX-10.7 EX-10.7

Exhibit 10.7

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

FIRST AMENDMENT TO

EXCLUSIVE DISTRIBUTION AGREEMENT

This First Amendment (this Amendment”) to Exclusive Distribution Agreement is entered into as of September 27, 2011 (the Effective Date”), by and between Zimmer Dental Inc., a Delaware corporation (“Zimmer”), and RTI Biologics, Inc., a Delaware corporation (“RTI”). Unless otherwise defined herein, capitalized terms shall have the meanings given to them in the Agreement (as defined below).

Recitals

A.    Zimmer and RTI entered into an Exclusive Distribution Agreement on September 30, 2010 (the Agreement”).

B.    Zimmer and RTI desire to amend the Agreement in accordance with Section 13.4 of the Agreement.

Agreement

For good and valuable consideration, the receipt and sufficiency of which is acknowledged by the execution and delivery of this Amendment, Zimmer and RTI agree to amend the Agreement as follows:

1.    Amendment to Agreement. Exhibit A to the Agreement shall be amended to include the following additional Implants:

 

Part
Numbers
US, LA,
APR,
CAN

  

Brand/Product Description

  

Transfer Fee
US/LA/APR/CN

    

Lead
time
Calendar
Days

    

Label
Shelf
Life

    

Minimum
Shelf Life
Upon
Receipt

 
   Human Bone Allograft            
68800    PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 0.5cc      [****]        [****]        [****]        [****]  
68801    PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 1cc      [****]        [****]        [****]        [****]  
68802    PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 2cc      [****]        [****]        [****]        [****]  
68803    PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 0.5cc      [****]        [****]        [****]        [****]  
68804    PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 1cc      [****]        [****]        [****]        [****]  
68805    PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 2cc      [****]        [****]        [****]        [****]  

 

- 1 -


NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

2.    Development Fee. As consideration for the development of the Implants set forth in Section 1 above, Zimmer shall pay the amount set forth on Quotation Number ###-###-#### R3, attached hereto as Annex A.

3.    Effect on the Agreement. Except as specifically amended above, the Agreement shall remain in full force and effect and is hereby ratified and confirmed. This Amendment is being effected in accordance with Section 13.4 of the Agreement.

[Remainder of Page Intentionally Blank]

 

- 2 -


NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its respective duly authorized representative as of the Effective Date.

 

RTI BIOLOGICS, INC.
By:   /s/ Roger Rose
Name:   Roger Rose
Title:   Executive Vice President
ZIMMER DENTAL, INC.
By:   /s/ Harold Flynn
Name:   Harold Flynn
Title:   President

 

- 3 -


NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

Annex A

Quotation Product Development

 

- 4 -


NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.

 

 

- 5 -